Figures
Abstract
Objective
To study the association of long-term statin use and the risk of low-energy hip fractures in middle-aged and elderly women.
Participants
Women aged 45–75 years initiating statin therapy between 1996 and 2001 with adherence to statins ≥80% during the subsequent five years (n = 40 254), a respective cohort initiating hypertension drugs (n = 41 610), and women randomly selected from the population (n = 62 585).
Main Outcome Measures
Incidence rate of and hazard ratio (HR) for low-energy hip fracture during the follow-up extending up to 7 years after the 5-year exposure period.
Results
Altogether 199 low-energy hip fractures occurred during the 135 330 person-years (py) of follow-up in the statin cohort, giving an incidence rate of 1.5 hip fractures per 1000 py. In the hypertension and the population cohorts, the rates were 2.0 per 1000 py (312 fractures per 157 090 py) and 1.0 per 1000 py (212 fractures per 216 329 py), respectively. Adjusting for a propensity score and individual variables strongly predicting the outcome, good adherence to statins for five years was associated with a 29% decreased risk (HR 0.71; 95% CI 0.58–0.86) of a low-energy hip fracture in comparison with adherent use of hypertension drugs. The association was of the same magnitude when comparing the statin users with the population cohort, the HR being 0.69 (0.55–0.87). When women with poor (<40%), moderate (40 to 80%), and good adherence (≥80%) to statins were compared to those with good adherence to hypertension drugs (≥80%) or to the population cohort, the protective effect associated with statin use attenuated with the decreasing level of adherence.
Citation: Helin-Salmivaara A, Korhonen MJ, Lehenkari P, Junnila SYT, Neuvonen PJ, Ruokoniemi P, et al. (2012) Statins and Hip Fracture Prevention – A Population Based Cohort Study in Women. PLoS ONE 7(10): e48095. https://doi.org/10.1371/journal.pone.0048095
Editor: Alberico Catapano, University of Milan, Italy
Received: June 8, 2012; Accepted: September 20, 2012; Published: October 29, 2012
Copyright: © 2012 Helin-Salmivaara et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by Kela (www.kela.fi) (grant 10/26/2007) and the Academy of Finland (www.aka.fi, desicion number 138255). The Social Insurance Institution and the Academy of Finland had no role in the design, analyses, interpretation of data, writing the report, or in the decision to submit the manuscript.
Competing interests: The authors have read the journal's policy and have the following conflicts: AHS, MK, RH have been funded by the grants from the Social Insurance Institution (10/26/2007) and the Academy of Finland (number 138255). PR has received a grant from Orion Pharmos Researh Foundation. RH is a member of the Advisory Board for Social and Medical Affairs of the SII. He has conducted consultancy for Orion Corporation as an Independent External Member of a Data Monitoring and Safety Committee in a clinical trial, and assisted Santen Pharmaceutical Co in pharmacokinetic calculations. PN, PL and SYTJ declare that no competing interests exist. The authors declare no other financial or non-financial (professional or personal) conflict of interests. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Introduction
Impact of statins (hydroxymethylglutaryl-CoA reductase inhibitors) on bone mineral density (BMD) has been debated since simvastatin and lovastatin were discovered to increase bone formation in animal experiments [1]. At the cellular level, there is no doubt that statins can affect bone formation. By inhibiting mevalonate pathway, statins decrease protein isoprenylation with a subsequent activation of bone morphogenetic protein-2 which contributes to osteoblast differentiation [1], [2]. Further support for a biological effect of statins comes from a recent experimental study which showed a drastic beneficial effect of locally administered simvastatin on fracture healing [3].
In clinical studies, observations on the effects of statins on bone have been inconsistent, especially in postmenopausal women, the most vulnerable population in terms of low energy fractures and bone health. While one meta-analysis showed the effect of statin use on various bone turn over markers in postmenopausal women [4], another more recent meta-analysis found no effect of statin use (1 year or less) on these markers in the same population [5]. A modest positive effect of statin use on hip BMD in women was found in two meta-analyses including various types of studies [4], [6]. This finding could not be verified, however, when only randomised trials were considered [5].
In theory, statins may have impact on both the BMD and micro architecture and molecular composition of bone. Overall, the role of BMD as a sole predictor of fractures has been questioned since only a small proportion of patients with a low-energy fracture have a decreased BMD [7]. Besides it, the micro architecture and molecular composition of the bone may play a significant role determining the bone quality [8].
Concerning hip fracture in women, a typical fracture in osteoporosis, statin use was associated with a 25% reduced risk (odds ratio [OR] 0.75; 95% CI 0.60–0.95) in a meta-analysis of nine studies [4]. When considering any fracture in women, the OR for a fracture associated with statin use was 0.80 in a meta-analysis of 11 studies (0.66–0.96) [9]. The risk of any fracture in women was analysed in two post-hoc studies of randomised trials on cardiovascular end points [10], [11]. In the AFCAPS/TexCAPS study, only one hip fracture occurred in each (lovastatin and placebo) group [10]. In the LIPID study, data on the risk of hip fracture in women was not presented [11] but the risk ratio for any fracture favoring pravastatin was 0.78 (95% CI 0.54–1.14) [5], [11].
We hypothesised that the exposure to statins should be at least as long as bone renewal time in order to demonstrate an association between statin use and such clinical outcomes as low-energy osteoporotic fractures. As the exact duration of bone renewal in hip in middle-aged or elderly women is not known, we arbitrarily set the minimum exposure time to five years. In several observational studies on statin use and risk of hip fracture in women, the exposure periods have been considerably shorter than five years [12], [13], [14]. Furthermore, in four prospective studies with a similar follow-up time, the analyses were intention-to-treat, the exposure being defined at baseline [15].
We performed a register-based study on the association of long-term statin use with the risk of low-energy, potentially osteoporotic fractures in middle-aged and elderly women. The primary aim was to compare the incidence of low-energy hip fracture between adherent users of statins and adherent users of antihypertensive drugs. The comparator group was selected in order to control for health seeking behaviour [16] and risk factors for cardiovascular diseases and fractures unavailable in the registers. Secondly, the incidence of low-energy hip fracture between statin users and a randomly selected population cohort was compared.
Methods
Sources of Data
We used data from administrative health databases generated through the universal health care and drug reimbursement systems covering the 5.4 million residents of Finland. We identified prescription records with the Prescription Register run since 1994 and managed by the Social Insurance Institution (SII) [17]. This register contains records of prescription drug purchases reimbursed to residents in non-institutional settings. For each purchase, the data include the dispensing date, the Anatomical Therapeutic Chemical classification code presented by the WHO [18], and the quantity dispensed. Permanent residents of the country are eligible to drug reimbursement and are therefore included in the Register, even if they did not get any reimbursement. Patients staying in a public nursing home or hospital without interruption for over 90 days are not eligible for drug reimbursement, and their purchases are not registered. We identified these patients from a separate SII register. For identifying patients entitled to higher rates of reimbursement because of certain severe, chronic conditions, such as coronary artery disease, diabetes, rheumatoid arthritis, and organ transplantations, we used the SII Special Reimbursement Register introduced in 1964. To be eligible for special reimbursement, a patient’s condition must meet explicit predefined criteria, and a written certificate by a physician is required.
We identified low-energy hip fractures from the Finnish Care Register, managed by the National Institute of Health and Welfare. The register, covering all Finnish hospitals and all hospitalizations regardless of the payer, includes individual administrative data on primary and secondary discharge diagnoses and the admission and discharge dates. The 10th revision of the International Classification of Diseases (ICD-10) has been in use since January 1, 1996. Properties of the fall (place and reason) leading to a hospitalised injury can be registered but it is not compulsory. The validity of the Finnish Care Register for hip fractures has been tested comparing medical records, prospective audit data, and the corresponding register data for 106 consecutive patients hospitalised for hip fracture in one hospital in 1999–2000 [19]. The sensitivity of hip fracture diagnosis in the register varied from 68.3% to 96.7%, depending on the specific site of the fracture.
The data from the above databases were linked anonymously using encrypted personal identifiers.
Cohorts and Exposure
Women aged 45–75 years by the end of the calendar year prior to each selection year were eligible to be included in the source population (Figure 1). Persons not considered eligible were those entitled to special drug reimbursement due to organ transplantations, severe renal insufficiency, severe gastrointestinal disease (mostly inflammatory bowel diseases), or Alzheimeŕs disease between 1996 and 2007. We excluded persons who died or were institutionalised during the 5-year exposure period since the cohort entry. From the hypertension cohort, we excluded persons who had purchased antihypertensive drugs in the year preceding the cohort entry. Next, we excluded from all cohorts those persons who had had any fracture in the 365 days prior to the cohort entry and those who had been hospitalised with any cancer diagnosis (except for non-melanoma skin cancer), with a diagnosis of pathological fracture, or with any fracture during the 5-year exposure period. The follow-up for the cohorts started 5 years since the cohort entry and ended when a person sustained a low-energy hip fracture, met any of the exclusion criteria mentioned above or on Dec 31, 2007 whichever came first (Figure 2). When sampling the cohorts, we strove to similar distributions of the cohort entry years.
*Poor adherence = prescribed days covered <80% in the 5-year exposure period and no more than 2 purchased statin/hypertension drug prescription in each year. †Hypertension drugs = beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers.
The figure is not to scale.
Statin cohort.
The statin cohort consisted of new users of statins from 1996 to 2001. The cohort entry was defined as the date of the first statin purchase. Those who had purchased statins in 1994 or 1995 were excluded, and each person was considered as an incident user only once. For the main analyses, the cohort was restricted to those persons adherent to statins in the 5-year exposure period. Adherence was defined as the Proportion of Days Covered (PDC) ≥80% [20]. We used the one-tablet-a-day dosage assumption when calculating the PDC, i.e. a person had to have purchased at least 1460 statin tablets during the 5 years (1825 days). Furthermore, at least 3 statin dispensations each year were required. In Finland, a drug can be reimbursed for no longer than 3 months’ therapy per purchase. Statin use after the exposure period was not considered.
For exposure-response relationship analyses, all statin initiators were further divided into three groups of adherence in the 5-year period: <40%, 40–80%, and ≥80% plus at least 3 purchases each year.
Hypertension cohort.
The hypertension cohort consisted of women who had not purchased drugs indicated in hypertension (imidazoline receptor agonists, beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, or calcium channel blockers) any time since 1994 until their first antihypertensive drug purchase between 1996 and 2001. The date of the first purchase defined the cohort entry. As diuretics are indicated also for several other conditions their use was not considered in the cohort definition. We restricted the hypertension cohort to those adherent to antihypertensive drugs or diuretics in the 5-year exposure period using the same definition for the adherence as in the statin cohort. Switching between drugs was considered as continuing the therapy. Persons that purchased statins in 1996–2006 could not be included in the hypertension cohort.
Population cohort.
The population cohort consisted of women randomly selected from the source population by using the Prescription Register of the SII. Those who had no statin purchases or who had no more than one statin purchase at any point in 1995–2006 were included. The cohort entry date was set at the 30th of June of the selection year.
Study End Points
We measured the occurrence of low-energy hip fractures over up to 7 years of follow up (Figure 2). A hip fracture leads to hospitalisation, and it is therefore comprehensively registered. A low-energy fracture was defined as a discharge diagnosis of hip fracture (ICD-10 codes S32.1, S32.3, S32.4, S72.0–S72.4, S72.7, and S72.8) without any other fracture code and without road-traffic accident codes as extrinsic factors. The codes of extrinsic factors such as “fall on the same level” and “fall on the snow or ice” were applied in the sensitivity analyses. The dates for death and institutionalisation were provided by the SII.
Patient Characteristics
Patients’ age at the end of the year prior to the cohort entry, hospital catchment area of the place of the residence, and the calendar year of the cohort entry were recorded. We assessed prescription drug use (insulin and other blood glucose lowering drugs, imidazoline receptor agonists, diuretics, beta blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, hormone replacement therapy, inhaled corticosteroids, bisphosphonates, calcitonin, thyroxin, phenytoin, selective serotonin reuptake inhibitors) within the 365 days prior to the cohort entry and co-morbidities (coronary artery disease, rheumatoid arthritis, cardiac insufficiency, cardiac arrhythmias, epilepsy, parkinsonism), as captured by the SII registers, any time before the cohort entry.
Statistical Analysis
We determined the incidence of hip fractures (per 1000 person-years) among the cohorts. The hazard ratio (HR) was estimated with Cox proportional-hazards regression. For confounder adjustment, we used the propensity score (PS) method. The propensity for adherence to statins was estimated separately in the statin versus hypertension cohort analysis and in the statin versus population cohort analysis by fitting a logistic regression model including the characteristics measured at cohort entry (see above). For the exposure-response analyses within the statin cohort, separate PS models were constructed for propensity for good versus moderate statin adherence and for good versus poor statin adherence, respectively. For other exposure-response analyses, several models were constructed modeling the PS for statin use in each case. When comparing the statin users with the population, the region of residence was excluded from the PS due to missing data (12% of the population cohort). In addition to the exposure group and the PS, the outcome models included those individual confounding factors that were the strongest predictors of the outcome (p<0.0001) [21]. When comparing the statin and hypertension cohorts, age, coronary heart disease, rheumatoid arthritis, use of antidiabetic drugs, and use of hormone replacement therapy were added in the model. In the statin versus population analyses, these were further supplemented by the use of diuretics, beta blockers, calcium channel blockers, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
The following exposure-response relationships were analysed by comparing: 1) the incidence in different groups of adherence to statins (<40%, 40–80%, ≥80% plus at least 3 purchases in each year) with the incidence in the adherent users of antihypertensive drugs and 2) with the incidence in the population cohort, and 3) the incidence across adherence groups within the statin cohort. For calculating P-values for trend, adherence to statins was defined as a continuous variable obtaining values from 0 (no statin exposure) to 3 (adherence to statins ≥80%).
In post hoc subgroup analyses, we first restricted the analyses to hip fractures caused by falls on the same level, or falls on snow or ice, by using the extrinsic factor codes provided in the Finnish Care Register. Second, we included those with any fracture within the 365 days prior to and during the exposure period to the study population. Finally, we examined the effect of various modifications of the PS on the HRs. First, use of antipsychotics, anxiolytics, hypnotics and sedatives, non-selective monoamine-reuptake inhibitors, monoamine oxidase type A inhibitors, or other antidepressants during the 365 days prior to the follow-up were added to the PS model. Second, in a separate sensitivity analyses, each of the following variables measured during the exposure period were included in the PS: alcohol-related hospitalisation, use of bisphosphonates acting on mevalonate pathway (pamidronic acid, alendronic acid, ibandronic acid, risedronic acid, zoledronic acid, risedronic acid in combination preparation with calcium, or risedronic acid with calcium and cholecalsiferol), and use of medication indicated in diabetes or hypertension.
The study size was based on a priori estimation. During a 10-year period among the population aged 50 years or older in Finland, the mean number of the first records with hip fracture diagnosis was 5564 per year in the early 2000’s [22]. In women, the number was 4050 per year (Sund, personal communication) yielding an incidence of 0.38% which we used as the incidence estimate for the unexposed. A risk ratio of 0.75 [4] with the two-sided significance level of 5% and 80% power was applied in calculations conducted by the Epi-Info software (http://wwwn.cdc.gov/epiinfo/). Aiming at the equal number of the exposed and unexposed, approximately 57600 person years would be needed in both groups.
We used SAS software (version 9.2; SAS Institute, Inc., Cary, NC, USA) for statistical analyses.
Ethical considerations.
The SII, the National Data Protection Agency, and the National Institute for Health and Welfare, Helsinki, Finland approved the study protocol. There was no legal requirement for an ethics committee approval because only de-identified register data were used and the persons in the registers were not contacted (the Finnish legislation at: http://www.finlex.fi/fi/laki/ajantasa/1999/19990488). No written consent from patients was required either.
Results
Of those 107 953 eligible women who initiated statin therapy in 1996–2001, 40 254 (37.3%) were included in the statin cohort (Figure 1). In the hypertension cohort, 41 610 (34.1%) out of 122 114 were included. As there were no exclusions based on adherence, 62 585 (90.2%) out of 69 705 eligible women were included in the population cohort. The cohorts differed in terms of age and co-morbidity distributions (Table 1). In the hypertension cohort, the distribution of the cohort entry year differed from that in the other two cohorts. The statin cohort was the oldest, mean age (SD) being 62.4 (7.5) years, with the highest prevalence of co-morbidities and use of various drugs at cohort entry. The population cohort was the youngest, 56.5 (8.7) years, with the lowest prevalence of co-morbidities.
In the statin cohort, 199 women (0.50%) sustained hip fracture during a mean of 3.36 years of follow-up, the respective figures in the hypertension and population cohorts were 312 (0.75%, 3.78 years) and 212 (0.34%, 3.46 years) (Table 2). The incidence rate was the highest in the hypertension cohort (2.0 hip fractures per 1000 person-years), followed by the statin (1.5) and the population cohorts (1.0). Of the statin cohort, 1 397 (3.45%) persons died during the follow-up. The respective figures in the hypertension and population cohorts were 2 256 (5.42%) and 1 691 (2.70%).
When adjusting for the propensity score and individual variables strongly predicting the outcome, good adherence to statins for five years was associated with a 29% decreased risk (HR 0.71; 95% CI 0.58–0.86) of a low-energy hip fracture when comparing with good adherence to antihypertensive drugs (Table 3). The association was of the same magnitude when comparing the statin users with the population cohort, HR being 0.69 (0.55–0.87).
Exposure-response Relationships
In order to analyse the exposure-response relationship, hip fracture incidence rates in women with poor (<40%), moderate (40–80%) and good (≥80% plus at least 3 purchases per year) adherence to statins, respectively, were compared with those in women with good adherence to the antihypertensive drugs. HRs decreased from 0.89 (0.70–1.12) through 0.73 (0.58–0.91) to 0.71 (0.58–0.86) (P for trend 0.0002, Table 4). The respective phenomenon was found in the statin versus population analyses; HRs decreased from 0.87 (0.68–1.10) through 0.71 (0.51–1.00) to 0.69 (0.55–0.87) (P for trend 0.0005, Table 4).
Within the statin cohort, hip fracture risk tended to be lower in the women with good adherence in comparison with the poor adherence group (HR 0.82; 0.65–1.03) but no difference was found between the moderate and good adherence groups (HR 1.01; 0.80–1.26) (Table 4).
Subgroup Analyses
The association between adherent use of statins and hip fracture did not change when the outcome was defined as the fracture caused by fall on the same level, or on the snow or ice (Table 5). Using the above end point definition, the HR was 0.69 (0.56–0.86) in the statin versus hypertension cohort comparison and 0.68 (0.52–0.88) in the statin versus population comparison.
Sensitivity Analyses
In sensitivity analyses, various variables measured during the exposure period were added to the PS but these additions did not affect the HRs (change in the estimate <10%) in the outcome models (Table 6).
Discussion
When women aged 50–80 years who had been adherent to statins for 5 years were compared with women adherent to antihypertensive drugs or with a cohort randomly selected from the population, statin users were at a 30% decreased risk of hip fracture over a mean of 3.57 years of follow-up. Furthermore, when women with poor, moderate, and good adherence to statins were compared to those with good adherence to antihypertensive drugs or to the population cohort, the protective effect associated with statin use increased with the increasing level of adherence.
Within the statin cohort, no difference in the risk of hip fractures was found between women with moderate (40–80%) and good adherence (≥80% and at least three prescriptions per year) while women with poor adherence (<40%) had a non-significant 20% increase in risk compared with those having good adherence. The finding, together with the results of other exposure-response analyses, may indicate that even less intensive statin exposure may be sufficient for improving bone health. When the analysis was adjusted for both the PS and the use of drugs indicated in diabetes or hypertension (including diuretics) during the follow-up the results of the statin/hypertension analysis did not change but the HR of the statin/population decreased to 0.64 (0.49–0.83) (Table 6).The baseline characteristics of the women with poor and good adherence differed; the mean age was higher and the frequencies of cardiovascular medications and coronary artery disease were higher in the women with good adherence (Table S2). Consequently, better general health in the group with good adherence cannot explain the results of the comparisons within the statin group.
The results of our study with a long exposure duration are concordant with the results from the post-hoc analyses of the LIPID study in women [5] and with the results of previous observational studies with heterogeneous exposure definitions in women [4]. However, the associations found in our analyses are not as strong as those published more recently. In a Danish population-based case-control study, 5-year statin adherence of at least 58% (defined as good) was associated with a 43% reduction (OR 0.57; 95% CI 0.39–0.84) in hip fracture risk in women [23]. In the same study, good statin adherence was associated with a 89% reduction (OR 0.11; 95% CI 0.02–0.66) in hip fracture risk in men aged 65 or younger. Furthermore, in a case-control study from the USA, already a 3-month statin use was associated with a 67% reduction (OR 0.23; 95% CI 0.09–0.57) in the hip fracture risk in elderly women using hormone replacement therapy [14]. These estimates suggest that benefits of statin use would exceed the achievements of conventional osteoporosis therapy [24] which does not seem biologically plausible. Inadequate adjustment for health seeking behavior and other types of residual confounding may partly explain the above exceptional findings.
The proposed protective effect of statins in bone may be explained by their biochemical effects on osteoblasts and osteoclasts. By interfering in the mevalonate pathway, statins suppress the synthesis of isoprenoids, such as farnesyl- and geranylgeranyl pyrophosphate [2], which mimics the effect of nitrogen-containing bisphosphonates inhibiting the same pathway at the level of farnesyl pyrophosphate synthase [25]. Simvastatin inhibits osteoclast differentiation [26], and both lipophilic [27] and hydrophilic statins [28] induce osteoblast differentiation. In bone of ovariectomized rats, simvastatin enhances the production of osteogenic proteins [29] and induces oestrogen receptor-alpha expression [30]. Since oestrogens slow down bone resorption and increase bone mineral density [31], induction of oestrogen receptor expression by statins, if functional also in postmenopausal women, could attenuate the effect of decrease in oestrogen levels or potentiate the effect of hormone replacement therapy on bone. Existence of a specific pharmacological effect is further supported by the finding that the fatty acid composition as such has no significant role in bone health [32].
Strengths
The strengths of our study include the comprehensive ascertainment of the outcome events, a long exposure period, a priori power analysis, the adjustment for several confounders, the observed exposure-response relationship, and the use of two different comparison groups. We chose the adherent hypertension cohort as a primary comparison group in order to control for health seeking behaviour and, additionally, for some covariates, such as body mass index (BMI), not available in the registers. In postmenopausal women, total body fat, clinically considered in BMI, is positively associated with the BMD [33], a predictor of fracture [34]. High BMI, in turn, is associated both with hypertension and hypercholesterolemia [35].
Limitations
The present study has weaknesses. Our definition of exposure, adherence to statin therapy, is two-dimensional; we cannot differentiate whether the associations or exposure-response relationships are due to accumulating dose or due to adherent behaviour, or both. Adherence to statin therapy may represent health seeking behaviour consisting of numerous elements, including use of preventive health services [36]. By choosing the adherent users of antihypertensive drug as the main comparator group we aimed to create groups similar in that respect. While doing that, however, we may have introduced selection bias. Women on antihypertensive drugs who initiated statin therapy during 1996–2006 were selected to the statin cohort and excluded from the hypertension cohort, the future statin initiation modifying the selection. Consequently, frail women, women with several co-morbidities, with less interest in health seeking, or with worse life-time prognosis, i.e. those with high risk for hip fracture may have been overrepresented in the hypertension cohort. In the statin versus population comparison, we primarily hypothesised to find a protective association due to health seeking behaviour of statin users [36]. Specially, in this analysis, uncontrolled health seeking behavior may have biased the effect estimates. We chose to study the incidence rate of low-energy hip fracture as hip fracture has been considered as an index fracture of osteoporosis. Hip fractures, however, result from falls that are associated with functional capacity, disability, and general health that we could not control for. We could not control for use of vitamin D and calcium supplements, dietary intake of them, physical activity, genetic factors, or frailty. Even though we controlled for oestrogen use, we did not take into account the duration or intensity of exposure. We did not study use of non-statin lipid lowering drugs as their consumption in Finland decreased during the study years from 12.8% in 1996 to 1.9% in 2006 of the total lipid lowering drug consumption measured as Defined Daily Doses/1000 inhabitants/day [37], [38].
Implications
Hip fracture can be considered as a burden to health care systems worldwide, although the overall rate of hip fractures varies across countries due to both genetic and environmental factors [39]. Contemporary pharmacotherapy, such as bisphosphonates, is rather ineffective in prevention of low-energy, osteoporotic fractures [40], [41], [42]. For example, the NNT for hip fracture prevention over 3 years in an osteoporotic subset of the population ranged from 48 (strontium ranelate) to 91 (bisphosphonates) [43]. Our results can be translated into a naivé number needed to treat (NNT) [44]; 628 postmenopausal women without prior hospitalisations for fractures need to use statins adherently for at least 5 years in order to prevent one future low-energy hip fracture over 3 years of follow-up. The respective NNT for 5 years of follow-up is 346. These estimates apply to a female population with cardiovascular risk factors (but without data on BMD), i.e. women using medication for hypercholesterolemia or for hypertension. In further studies, impact of time-varying confounding factors and the impact of various exposure durations on fracture risk are worth exploring. Especially, the cumulative dose may be relevant as in animal studies the doses have been ten times that used in routine clinical practice [1].
Conclusions
In conclusion, our large population-based study suggests that long-term exposure to statins is associated with a reduced risk of low-energy hip fracture in women aged 50–80 years without prior hospitalised fractures. Although the absolute benefit is small, some extra benefit in bone health may be achieved when statins are used for their main indication.
Supporting Information
Table S1.
Selected characteristics of the persons in the study cohorts.
https://doi.org/10.1371/journal.pone.0048095.s001
(PDF)
Table S2.
Selected characteristics of the persons within the statin cohort.
https://doi.org/10.1371/journal.pone.0048095.s002
(PDF)
Acknowledgments
We thank Hilkka Ruuska and Kristiina Tyrkkö of the Social Insurance Institution for their data management skills.
Author Contributions
Conceived and designed the experiments: AHS MJK PL SYTJ PN RH. Performed the experiments: AHS MJK. Analyzed the data: AHS MJK. Contributed reagents/materials/analysis tools: AHS MJK. Wrote the paper: AHS MJK PL PJN SYT PR RH.
References
- 1. Mundy G, Garrett R, Harris S, Chan J, Chen D, et al. (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286: 1946–1949.
- 2. Horiuchi N, Maeda T (2006) Statins and bone metabolism. Oral Dis 12: 85–101.
- 3. Fukui T, Ii M, Shoji T, Matsumoto T, Mifune Y, et al. (2012) Therapeutic effect of local administration of low dose simvastatin-conjugated gelatin hydrogel for fracture healing. J Bone Miner Res 27: 1118–31.
- 4. Hatzigeorgiou C, Jackson JL (2005) Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int 16: 990–998.
- 5. Yue J, Zhang X, Dong B, Yang M (2010) Statins and bone health in postmenopausal women: a systematic review of randomized controlled trials. Menopause 17: 1071–1079.
- 6. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY (2007) Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 40: 1581–1587.
- 7. Baim S, Leslie WD (2012) Assessment of fracture risk. Curr Osteoporos Rep 10: 28–41.
- 8. Kijowski R, Tuite M, Kruger D, Munoz Del Rio A, Kleerekoper M, et al. (2012) Evaluation of trabecular micro-architecture in non-osteoporotic post-menopausal women with and without fracture. J Bone Miner Res 27: 1494–500.
- 9. Toh S, Hernandez-Diaz S (2007) Statins and fracture risk. A systematic review. Pharmacoepidemiol Drug Saf 16: 627–640.
- 10. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, et al. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615–1622.
- 11. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, et al. (2001) Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 357: 509–512.
- 12. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, et al. (2000) Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355: 2185–2188.
- 13. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC (2002) Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 162: 537–540.
- 14. Bakhireva LN, Shainline MR, Carter S, Robinson S, Beaton SJ, et al. (2010) Synergistic effect of statins and postmenopausal hormone therapy in the prevention of skeletal fractures in elderly women. Pharmacotherapy 30: 879–887.
- 15. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, et al. (2004) Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 164: 146–152.
- 16. Dormuth CR, Patrick AR, Shrank WH, Wright JM, Glynn RJ, et al. (2009) Statin adherence and risk of accidents: a cautionary tale. Circulation 119: 2051–2057.
- 17. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, et al. (2010) The Nordic Countries as a Cohort for Pharmacoepidemiological Research. Basic Clin Pharmacol Toxicol 106: 86–94.
- 18.
WHO. About the ATC/DDD system. http://www.whocc.no/atcddd/. Accessed 4 Apr, 2008, 2008.
- 19. Sund R, Nurmi-Luthje I, Luthje P, Tanninen S, Narinen A, et al. (2007) Comparing properties of audit data and routinely collected register data in case of performance assessment of hip fracture treatment in Finland. Methods Inf Med 46: 558–566.
- 20. Leslie SR, Gwadry-Sridhar F, Thiebaud P, Patel BV (2008) Calculating medication compliance, adherence and persistence in administrative pharmacy claims databases. Pharmaceutical programming 1: 13–19.
- 21. Patrick AR, Schneeweiss S, Brookhart MA, Glynn RJ, Rothman KJ, et al. (2011) The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf 20: 551–559.
- 22. Sund R (2007) Utilization of routinely collected administrative data in monitoring the incidence of aging dependent hip fracture. Epidemiol Perspect Innov 4: 2.
- 23. Rejnmark L, Vestergaard P, Mosekilde L (2006) Statin but not non-statin lipid-lowering drugs decrease fracture risk: a nation-wide case-control study. Calcif Tissue Int 79: 27–36.
- 24. Han SL, Wan SL (2012) Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials. Int J Clin Pract 66: 199–209.
- 25. van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Lowik CW, et al. (2003) Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 33: 805–811.
- 26. Yamashita M, Otsuka F, Mukai T, Yamanaka R, Otani H, et al. (2010) Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling. Regul Pept 162: 99–108.
- 27. Maeda T, Matsunuma A, Kurahashi I, Yanagawa T, Yoshida H, et al. (2004) Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. J Cell Biochem 92: 458–471.
- 28. Monjo M, Rubert M, Ellingsen JE, Lyngstadaas SP (2010) Rosuvastatin promotes osteoblast differentiation and regulates SLCO1A1 transporter gene expression in MC3T3-E1 cells. Cell Physiol Biochem 26: 647–656.
- 29. Ho ML, Chen YH, Liao HJ, Chen CH, Hung SH, et al. (2009) Simvastatin increases osteoblasts and osteogenic proteins in ovariectomized rats. Eur J Clin Invest 39: 296–303.
- 30. Li X, Song QS, Wang JY, Leng HJ, Chen ZQ, et al. (2011) Simvastatin induces estrogen receptor-alpha expression in bone, restores bone loss, and decreases ERalpha expression and uterine wet weight in ovariectomized rats. J Bone Miner Metab 29: 396–403.
- 31. Rosen CJ (2005) Clinical practice. Postmenopausal osteoporosis. N Engl J Med 353: 595–603.
- 32.
Virtanen JK, Mozaffarian D, Willett WC, Feskanich D Dietary intake of polyunsaturated fatty acids and risk of hip fracture in men and women. Osteoporos Int DOI: 10.1007/s00198-012-1903-3. [Epub ahead of print].
- 33. Reid IR, Ames R, Evans MC, Sharpe S, Gamble G, et al. (1992) Determinants of total body and regional bone mineral density in normal postmenopausal women–a key role for fat mass. J Clin Endocrinol Metab 75: 45–51.
- 34. Cummings SR, Black D (1995) Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies. Am J Med 98: 24S–28S.
- 35. Jousilahti P, Tuomilehto J, Vartiainen E, Pekkanen J, Puska P (1996) Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle-aged men and women in eastern Finland. Circulation 93: 1372–1379.
- 36. Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, et al. (2007) Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 166: 348–354.
- 37.
National Agency for Medicines and Social Insurance Institution (1997) Finnish Statistics on Medicines 1996. Helsinki.
- 38.
National Agency for Medicines and Social Insurance Institution (2007) Finnish Statistics on Medicines 2006. Helsinki.
- 39.
Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, et al.. (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int DOI: 10.1007/s00198-012-1964-3. [Epub ahead of print].
- 40.
Wells G, Cranney A, Peterson J, Boucher M, Shea B, et al.. (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev: CD004523.
- 41.
Wells GA, Cranney A, Peterson J, Boucher M, Shea B, et al.. (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev: CD001155.
- 42.
Wells GA, Cranney A, Peterson J, Boucher M, Shea B, et al.. (2008) Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev: CD003376.
- 43. Ringe JD, Doherty JG (2010) Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatol Int 30: 863–869.
- 44. Barrat AL, Wyer PC, Gyatt G, Simpson JM (2005) NNT for studies with long-term follow-up. CMAJ 172: 613–615.